SpyGlass Pharma (SGP) Reports Four Year Trial Data, Is It Still Below Fair Value?
SpyGlass Pharma (SGP) is back on investor radars after reporting four-year first-in-human trial data for its Bimatoprost Drug Pad IOL System in glaucoma and ocular hypertension patients.
SpyGlass Pharma’s share price has climbed 44.03% on a 90 day share price return and 24.81% on a 30 day share price return. The 13.94% 7 day share price return suggests momentum has been building around these trial updates rather than fading.
Scan beyond SpyGlass Pharma and see how other ophthalmology and biotech plays are reacting to similar clinical catalysts with our hand picked 18 high quality undiscovered gems.
After a 44% move in three months and positive four year trial data, SpyGlass Pharma is no longer flying under the radar. Does the current price still compensate you for the clinical and funding risk ahead?
Most Popular Narrative: 26% Undervalued
SpyGlass Pharma closed at $32.45, while the widely followed narrative pegs fair value at $44 based on a detailed long term glaucoma opportunity and funding runway.
The plan to complete Phase III BIM‑IOL enrollment in 2027, deliver top line intraocular pressure data in Q4 2027 and file an NDA in 2028 sets up a defined path toward a potential 2029 U.S. launch. This timeline could begin to convert SpyGlass Pharma’s estimated US$13b cataract surgery glaucoma opportunity into revenue.
See why 1 investors see SpyGlass Pharma as 26% undervalued.
Result: Fair Value of $44 (UNDERVALUED)
Still, the SpyGlass Pharma story hinges on BIM IOL clearing Phase III without setbacks, and on reimbursement and pricing lining up with that US$13b glaucoma surgery thesis.
Find out about the key risks to this SpyGlass Pharma narrative.
Next Steps
Whether you are optimistic or cautious after this SpyGlass Pharma update, you should move quickly to review the numbers yourself, pressure test the assumptions, and weigh the 3 important warning signs.
Looking for more investment ideas beyond SpyGlass Pharma?
Do not stop with SpyGlass Pharma. Broaden your watchlist now and let data driven filters surface opportunities you might otherwise never see.
- Target resilient returns by focusing on sturdier balance sheets with a 30 resilient stocks with low risk scores that filters for companies with lower overall risk profiles.
- Prioritise financial strength and consistency by running a list of solid balance sheet and fundamentals (25 results) that highlights businesses with cleaner debt positions and healthier fundamentals.
- Hunt for potential mispricings by scanning a 29 high quality undervalued stocks that brings together quality metrics and valuation checks in one place.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com